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Abstract Athletes who abuse recombinant human eryth-
ropoietin (rhEPO) consider only the benefit to performance
and usually ignore the potential short and long-term liabil-
ities. Elevated haematocrit and dehydratation associated
with intense exercise may reveal undetected cardiovascular
risk, but the mechanisms underlying it remain to be fully
explained. This study aimed to evaluate the cardiovascular
effects of rhEPO in rats under chronic aerobic exercise. A
ten week protocol was performed in four male Wistar rat
groups: control—sedentary; rhEPO—50 IU kg-1, 3 times/
wk; exercised (EX)—swimming for 1 h, 3 times/wk;
EX ? rhEPO. One rat of the EX ? rhEPO group suffered a
sudden death episode during the week 8. rhEPO in trained
rats promoted erythrocyte count increase, hypertension,
heart hypertrophy, sympathetic and serotonergic overacti-
vation. The suddenly died rat’s tissues presented brain with
vascular congestion; left ventricular hypertrophy, together
with a ‘‘cardiac-liver’’, suggesting the hypothesis of heart
failure as cause of sudden death. In conclusion, rhEPO
doping in rats under chronic exercise promotes not only the
expected RBC count increment, suggesting hyperviscosity,
but also other serious deleterious cardiovascular and
thromboembolic modifications, including mortality risk,
which might be known and assumed by all sports authori-
ties, including athletes and their physicians.
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Introduction
Erythropoietin (EPO) is a glycoprotein hormone synthe-
sized predominantly in the kidneys, which stimulates pro-
liferation and maturation of erythroid cells in the bone
marrow [1]. The production of recombinant human eryth-
ropoietin (rhEPO), which has been widely used for cor-
rection of anaemia, allowed many patients for the first time
to resume their normal daily activities due to increased
energy [2].
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The increase in circulating red blood cells (RBCs) may
be used to increase oxygen delivery to muscles, improving
performance in sport [3]. The availability of rhEPO
allowed its use in doping. As soon as the anti-doping
authorities were able to distinguish between the endoge-
nous and the rhEPO [4], the scandal of its use in sport was
revealed, with particular emphasis to cycling and cross-
country skiing, compared to other sports modalities [5, 6].
Sports authorities prohibited the use of rhEPO in 1988. The
idea was, first, to limit the degree of health risk and, sec-
ond, the degree of performance enhancement.
Athletes who abuse rhEPO consider only the benefit to
performance and usually ignore the potential short- and
long-term liabilities [7, 8]. In the early 1990s, there was a
considerable speculation about the involvement of rhEPO
doping in the death of professional cyclists [8, 9]. The
artificial increase in RBC count and haematocrit, further
enhanced by dehydratation during prolonged exercise,
predisposes to thromboembolic complications, which
might be connected to sudden death in sport practice [10].
However, the cellular/molecular mechanisms underlying
those sudden death episodes are poorly clarified, as well
as whether rhEPO use was linked to this outrageous
phenomenon.
The purpose of this study was to evaluate the cardio-
vascular effects of rhEPO treatment on rats under chronic
aerobic exercise; we also studied the probable cause of
sudden death occurred in one rat under exercise practice
and rhEPO treatment.
Materials and Methods
Animals and Experimental Protocol
Male Wistar rats (Charles River Laboratories Inc., Barce-
lona, Spain), weighting 220–250 g, were maintained in an
air conditioned room (22–24C) with humidity of 60%,
subjected to 12-h dark-light cycles and given standard rat
chow (AO4, Panlab, Letica, Barcelona, Spain) and water
ad libitum. All experiments with animals were performed
in accordance with the European Convention for the Pro-
tection of Vertebrate Animals used for Experimental and
other Scientific Purposes (Council of Europe no 123,
Strasbourg, 1985), as well as with ethical laws of the
National Institutions for Science and Technology.
After a period of adaptation of at least 2 weeks, four
groups (n = 7 each) were evaluated for 10 weeks treat-
ment: (a) control—sedentary; (b) rhEPO—50 IU/Kg/3x/
wk of s.c. beta-EPO (Recormon, Roche Pharmaceuti-
cals); (c) exercised (EX)—swimming training (1 h, 3x/
wk); (d) swimming exercised ? rhEPO (EX ? rhEPO).
The swimming groups were submitted to a previous
adaptation period of 1 week in order to minimize the stress
caused by water. These sessions started with 15 min in the
first day, with an increment of 5 min each day until
achieved a period of continuous 60 min. After this period,
the exercise was performed for 1 h, 3x/week, in a tem-
perature-controlled bath set at 35 ± 1C, for 10 weeks.
Excepting one animal of the EX ? rhEPO group, which
suffered a sudden death episode during an exercise session
(week 8), all the animals have completed the 10-week
protocol.
Body weight (BW) was monitored during the study, and
blood pressure (BP) and heart rate (HR) measured using a
tail-cuff sphygmomanometer LE 5001 (Letica, Barcelona,
Spain).
Sample Collection and Preparation
Blood
At the end of treatments, the rats were subjected to intra-
peritoneal anaesthesia with a 2 mg kg-1 BW of a 2:1 (v:v)
50 mg ml-1 ketamine (Ketalar, Parke-Davis, Lab. Pfeizer
Lda, Seixal, Portugal) solution in 2.5% chlorpromazine
(Largactil, Rhoˆne-Poulenc Rorer, Lab. Vito´ria, Amadora,
Portugal), and blood samples were immediately collected
by venipuncture from the jugular vein into syringes without
anticoagulant (for serum samples collection) or with the
appropriate anticoagulant: EDTA, heparin or a solution of
ACD (acid citrate-dextrose). Blood was centrifuged (160 g
for 10 min. at 20C) to obtain platelet-rich plasma (PRP),
which was then centrifuged (730 g for 10 min. at 20C) to
obtain the platelet pellet and poor platelet plasma (PPP).
Tissues
The rats were killed by cervical dislocation, and the heart,
the adrenals, the kidneys, the liver and the gastrocnenius
muscle were immediately removed, placed in ice-cold
Krebs’ buffer and carefully cleaned of adherent fat and
connective tissue. The BW and the weights of heart (HW),
left ventricle (LVW), adrenals (AW), kidney (KW), liver
(LW) and muscle (MW) were measured in all the rats
under study in order to be used as trophy indexes. The
following tissues were removed from the rat that suffered a
sudden death episode during an exercise session after
8 weeks of treatment: lungs, kidneys, brain, heart/left
ventricle and liver. Tissues were analyzed for histomor-
phology with haematoxylin–eosin (H&E) staining.
Serum Epo Concentration and Haematological Data
Serum erythropoietin was measured by using an immuno-
assay kit (R&D Systems, Minneapolis, USA). Results were
expressed in pg/ml. Red blood cell (RBC) count, haema-
tocrit (Hct), haemoglobin (Hb) concentration, haemato-
logical indices [mean cell Hb (MCH) and mean cell Hb
concentration (MCHC), mean cell volume (MCV) and red
cell distribution width (RDW)], platelet count and platelets
indices [plaquetocrit (PCT), mean platelet volume (MPV)
and platelet distribution width (PDW)] were assessed in an
automatic Coulter Counter (Beckman Coulter Inc., USA,
CA).
Renal and Liver Function and Lipid Profile
Serum creatinine, urea and uric acid concentrations were
used as renal function indexes, and aspartate (AST) and
alanine aminotransferase (ALT) levels were assessed for
liver evaluation, through automatic validated methods and
equipments (Hitachi 717 analyser).
Serum total cholesterol (Total-c) and triglycerides (TGs)
were analysed on a Hitachi 717 analyser (Roche Diag-
nostics Inc., MA, USA) using standard methods.
Catecholamine and Serotonin Assay
Noradrenaline (NA) and adrenaline (A) concentrations in
plasma, platelet, adrenals and brain, as well as plasma,
platelet and brain 5-hydroxy-tryptamine (5-HT) and 5-hy-
droxyindoleacetic acid (5-HIAA) contents were evaluated
by high performance liquid chromatography with electro-
chemical detection (HPLC-ED), according to previously
described protocol [11], using appropriate standards
(Sigma Chemical Co., St. Louis, MO, USA) and software
(Gilson 710). Concentrations were expressed in ng/ml for
plasma and platelets and lg/g wet tissue for adrenals and
brain.
Serum Inflammatory Profile and Redox Status
Inflammatory Markers
Serum levels of interleukin 2 (IL-2), IL-1b, transforming
growth factor b1 (TGF-b1) and tumour necrosis factor a
(TNF-a) were measured by ultrasensitive Quantikine
ELISA kits (R&D Systems, Minneapolis, USA) and
C-reactive protein (CRP) by using an ELISA kit from
Helica Biosystems, Inc. (Fullerton, CA, USA). All assays
were performed in duplicate.
Redox Status
The thiobarbituric acid reactive-species (TBARs) assay
was used to assess serum and muscle products of lipid
peroxidation, via malondialdehyde (MDA), according to
previously described protocol [12]. Samples were analysed
spectrophotometrically at 532 nm using 1,1,3,3-tetrameth-
oxypropane as external standard. The serum concentration
of lipid peroxides (in MDA) was expressed as lmol/l.
Serum 3-nitrotyrosine (3-NT), which is an index of per-
oxynitrite formation, was measured through an enzymatic
immunoassay (HyCult biotechnology b.v., Uden, Nether-
lands). Ferric-reducing antioxidant potential (FRAP) assay
was used to estimate serum total antioxidant status (TAS)
[13].
Data Analysis
For statistical analysis, we used the Statview 4.53 software
from Abacus Concepts Inc. (Berkeley, CA, USA). Results
are presented as mean ± standard error of the mean
(s.e.m.). Comparisons between groups were performed
using Factorial (two-way) ANOVA and Fisher’s PLSD
test. Significance was accepted at P less than 0.05.
Results
General Characterization: Serum EPO Concentration
and Haematological Data
Serum EPO concentrations at the end of treatments were
significantly higher (P \ 0.05) in the rhEPO rats when
compared with the controls, while no significant differences
were encountered in the EX animals. rhEPO treatment in
the exercised rats (group EX ? rhEPO) did not signifi-
cantly modify the serum EPO concentrations (Table 1).
The rats under rhEPO treatment showed an increase in
RBC count (P \ 0.05) when compared with the control.
This was accompanied by increased (P \ 0.05) MCHC and
MCV (Table 1). The exercised rats demonstrated no rele-
vant changes concerning haematological data, excepting
higher MCHC versus the control animals. In the exercised
rats treated with rhEPO, there was a statistically significant
increment in RBC count, together with a trend to increased
Hb and Hct versus the EX rats without rhEPO therapy
(Table 1). Platelet count and PCT were unchanged between
groups, only demonstrating a trend to higher values in this
group (data not shown).
Effect of rhEPO in Renal and Liver Function and Lipid
Profile in Chronic Exercise
Urea content was lower (P \ 0.05) in the rhEPO group
versus control, without significant changes on creatinine
and uric acid. Exercised rats also presented significantly
lower values of urea (P \ 0.05) and uric acid (P \ 0.01).
This reduction was prevented in the rats under exercise and
rhEPO treatment (EX ? rhEPO; Table 2).
Serum AST was unchanged between groups, but there
was a higher value of ALT in the rhEPO and in the EX rats
versus the control. The change in the EX rats was not
prevented by concomitant rhEPO treatment (Table 2).
Concerning the lipid profile, while the rhEPO rats pre-
sented a trend to higher Total-c contents and significantly
increased TGs levels (P \ 0.05), the EX animals showed
the opposite profile. The values encountered for the
EX ? rhEPO rats were similar to those of the EX animals
(Table 2).
RhEPO Promotes/Aggravates Hypertension,
Tachycardia and Cardiac Hypertrophy in Chronic
Exercise
Blood pressure (SBP, DBP and MBP) and HR values were
higher in the rhEPO group when compared with control. The
same pattern was found for EX group. In exercised animals,
rhEPO treatment further increased blood pressures
(P \ 0.001) and HR (P \ 0.05; Fig. 1). Body weight
showed a lower value (P \ 0.05) in EX rats (0.46 ± 0.10 kg)
versus control (0.51 ± 0.01 kg), without further changes
between groups. HW and HW/BW were significantly higher
Table 1 General characterization: serum EPO concentration and haematological data
Parameters Sedentary Swimming
Control (n = 7) rhEPO (n = 7) EX (n = 7) EX ? rhEPO (n = 7)
Serum [EPO] (pg/ml) 22.25 ± 1.00 35.75 ± 10.1a 27.83 ± 1.50 25.75 ± 2.24
Haematological data
RBC count (91012/l) 7.31 ± 0.16 7.67 ± 0.08a 7.59 ± 0.15 8.23 ± 0.14b
Hb (g/dl) 14.45 ± 0.65 14.11 ± 0.15 14.86 ± 0.25 15.45 ± 0.45
Hct (%) 41.45 ± 1.65 39.59 ± 0.45 41.40 ± 0.82 44.05 ± 1.45
MCH (pg) 19.80 ± 1.30 18.76 ± 0.22 19.60 ± 0.34 18.75 ± 0.25
MCHC (g/dl) 34.80 ± 0.20 35.75 ± 0.18a 35.93 ± 0.21a 35.05 ± 0.05
MCV (fl) 56.80 ± 3.50 52.48 ± 0.60a 54.61 ± 1.13 53.55 ± 0.85
RDW (%) 15.25 ± 0.65 15.89 ± 0.38 14.84 ± 0.55 14.25 ± 0.15
Results are means ± s.e.m. of n rats per group
EPO erythropoietin; Hb haemoglobin; MCH mean corpuscular haemoglobin; MCHC mean corpuscular haemoglobin concentration; MCV mean
corpuscular volume; RBC red blood cell and rhEPO recombinant human erythropoietin
a P \ 0.05, aa P \ 0.01 and aaa P \ 0.001 versus the sedentary group (control)
b P \ 0.05, bb P \ 0.01 and bbb P \ 0.001 versus the Swimming group without rhEPO (exercise: EX)
Table 2 Effects of rhEPO on renal and liver function and lipid profile
Parameters Sedentary Swimming
Control (n = 7) rhEPO (n = 7) EX (n = 7) EX ? rhEPO (n = 7)
Renal function
Urea (mg/dl) 18.84 ± 0.55 17.37 ± 0.46a 17.35 ± 0.26a 18.60 ± 0.63
Creatinine (mg/dl) 0.57 ± 0.01 0.54 ± 0.02 0.57 ± 0.01 0.56 ± 0.01
Uric acid (mg/dl) 0.68 ± 0.05 0.77 ± 0.05 0.40 ± 0.06aa 0.50 ± 0.03
Liver function
AST (IU/l) 27.20 ± 0.37 27.50 ± 0.50 30.60 ± 2.84 32.40 ± 2.27
ALT (IU/l) 50.20 ± 0.86 70.00 ± 2.28aaa 65.20 ± 1.59aaa 63.50 ± 2.63
Lipid profile
Total-c (mg/dl) 53.17 ± 1.66 55.00 ± 1.94 43.67 ± 1.20aa 38.25 ± 1.18
TGs (mg/dl) 151.80 ± 7.17 185.60 ± 16.21a 131.00 ± 5.58 136.33 ± 8.03
Results are means ± s.e.m. of n rats per group
ALT alanine aminotransferase; AST aspartate aminotransferase; rhEPO recombinant human erythropoietin; TGs triglycerides and Total-c total
cholesterol
a P \ 0.05, aa P \ 0.01 and aaa P \ 0.001 versus the sedentary group (control)
b P \ 0.05, bb P \ 0.01 and bbb P \ 0.001 versus the Swimming group without rhEPO (exercise: EX)
in rhEPO group versus control, together with significant
lower LVW and LVW/BW. In the rats under exercise prac-
tise, rhEPO treatment promoted a further increment in HW
and HW/BW, with a trend to increased values of LVW and
LVH/BW (Fig. 1). Concerning the other tissues, the changes
to report were in the rhEPO group, there was a significant
reduction in (P \ 0.05) KW/BW (2.56 ± 0.05 g kg-1)
versus the control (2.86 ± 0.09 g kg-1), while in the rats
under exercise, there were higher values of AW/BW
(0.148 ± 0.02 g kg-1; P \ 0.05) and MW/BW (47.75 ±
0.59 g kg-1; P \ 0.01) versus the control (0.108 ± 0.01
and 44.90 ± 0.91, respectively).
RhEPO Promotes Peripheral Sympathetic
and Serotonergic Overactivation in Chronic Exercise
The rhEPO-treated rats presented a trend to higher values
of plasma NA and AD versus control, together with lower
platelet contents of both catecholamines and of NA in
adrenals. Exercised rats also showed a trend to higher
concentration of plasma NA and significantly higher
(P \ 0.001) concentration of platelet NA and AD, as well
as lower content in the adrenals, which was statistically
significant for AD (P \ 0.05). In the EX ? rhEPO rats,
however, the plasma NA and AD were significantly
(P \ 0.05) higher when compared with EX group, which
was accompanied by lower platelet AD content and a trend
to higher concentration of this amine in adrenals and brain
(Table 3). Concerning serotoninergic measures, while
plasma 5-HT values were lower (P \ 0.01) in rhEPO rats
versus control, 5-HIAA levels were higher (P \ 0.01).
Similar pattern was found for the EX animals (P \ 0.05).
The platelet levels showed an inverse profile. In the rats
under exercise and rhEPO treatment, the plasma 5-HT
(P [ 0.001) and 5-HIAA (P \ 0.05) concentrations were
substantially higher than those observed in EX animals,
and the platelet and brain levels were maintained identical
to those of the EX rats (Table 3).
Effect of rhEPO in Serum Inflammatory Profile
and Redox Status Markers in Chronic Exercise
In the rhEPO rats, there were significantly (P \ 0.05)
higher values of TNF-a and TGF-b1 versus control. No
significant changes were obtained for the EX group versus
control. In the EX ? rhEPO group, excepting the higher
(P \ 0.05) values of TGF-b1 versus the EX group, there
was no further differences between the groups (Table 4).
In the rhEPO-treated rats (rhEPO group), there was an
antioxidant effect, with an increment in TAS (P \ 0.001)
Fig. 1 Effects of rhEPO on
blood pressures (systolic,
diastolic and mean BP), heart
rate and heart and left ventricle
weights and trophy indexes in
the rats of the 4 groups under
study for 10 weeks: control
(sedentary: Sed), rhEPO
(50 IU/kg s.c., 3 times/wk;
exercised (EX), which swam
for 1 h, 3 times/wk and
EX ? rhEPO. Results are
means ± s.e.m. of 7 rats per
group. * P \ 0.05, ** P \ 0.01
and *** P \ 0.001
and a decrease in 3-NT content (P \ 0.05). Similar pattern
was found for the EX group versus control, particularly due
to a decrease in serum MDA (P \ 0.05). However, in the
rats of the EX ? rhEPO group, no relevant changes were
encountered for the redox status markers, being the values
identical to those of the control group (Table 4).
Table 3 Effects of rhEPO on peripheral and central catecholamine and serotonin measures
Parameters Sedentary Swimming
Control (n = 7) rhEPO (n = 7) EX (n = 7) EX ? rhEPO (n = 7)
Catecholamines measures
NA—Plasma (ng/ml) 3.71 ± 0.60 4.81 ± 0.37 5.10 ± 0.96 9.32 ± 1.43b
Platelet (ng/ml) 4.54 ± 0.61 0.60 ± 0.08aaa 8.02 ± 0.68aaa 7.01 ± 0.47
Adrenals (lg/g) 164.1 ± 8.0 130.4 ± 9.6a 149.8 ± 15.8 133.8 ± 7.9
Brain (ng/g) 0.20 ± 0.004 0.18 ± 0.007 0.21 ± 0.008 0.19 ± 0.008
AD—Plasma (ng/ml) 1.48 ± 0.21 1.52 ± 0.06 1.04 ± 0.09 1.96 ± 0.18b
Platelet (ng/ml) 0.69 ± 0.04 0.36 ± 0.08aa 9.15 ± 2.26aaa 0.50 ± 0.09bbb
Adrenals (lg/g) 626.0 ± 47.6 602.0 ± 66.7 433.1 ± 24.6a 579.4 ± 40.6
Brain (ng/g) 2.03 ± 0.09 2.38 ± 0.18 1.79 ± 0.25 2.57 ± 0.15b
Serotonergic measures
5-HT—Plasma (ng/ml) 18.56 ± 1.46 5.82 ± 0.60aaa 11.08 ± 0.65a 30.07 ± 4.45bbb
Platelet (ng/ml) 556.7 ± 40.9 830.0 ± 27.2aaa 1610.8 ± 55.1aaa 1640.4 ± 39.6
Brain (lg/g) 0.25 ± 0.01 0.30 ± 0.01a 0.24 ± 0.01 0.22 ± 0.01
5-HIAA—Plasma (ng/ml) 11.53 ± 0.93 17.56 ± 1.20aa 18.00 ± 2.94a 25.07 ± 2.38b
Platelet (ng/ml) 3.92 ± 0.24 2.74 ± 0.18aa 2.99 ± 0.22a 3.68 ± 0.30
Brain (lg/g) 0.13 ± 0.004 0.12 ± 0.007 0.13 ± 0.005 0.13 ± 0.006
Results are means ± s.e.m. of n rats per group
A adrenaline; NA noradrenaline; rhEPO recombinant human erythropoietin; 5-HT 5-hydroxy-tryptamine; 5-HIAA 5-hydroxyindoleacetic acid
a P \ 0.05, aa P \ 0.01 and aaa P \ 0.001 versus the sedentary group (control)
b P \ 0.05, bb P \ 0.01 and bbb P \ 0.001 versus the Swimming group without rhEPO (exercise: EX)
Table 4 Effects of rhEPO on serum inflammatory profile and redox status markers
Parameters Sedentary Swimming
Control (n = 7) rhEPO (n = 7) EX (n = 7) EX ? rhEPO (n = 7)
Inflammatory markers
CRP (lg/ml) 26.68 ± 0.88 24.82 ± 0.76 24.22 ± 1.06 25.77 ± 1.21
IL-1b (pg/ml) 25.55 ± 1.69 25.95 ± 0.75 25.84 ± 1.38 23.96 ± 1.27
IL-2 (pg/ml) 44.67 ± 7.48 39.59 ± 4.75 51.48 ± 4.11 59.08 ± 3.76
TNF-a (pg/ml) 12.13 ± 0.65 14.18 ± 0.79a 12.62 ± 0.76 12.69 ± 0.59
TGF-b1 (pg/ml) 315.2 ± 13.2 380.2 ± 18.8a 317.8 ± 15.1 375.7 ± 23.5b
Redox status
MDA (lmol/l) 0.40 ± 0.02 0.38 ± 0.04 0.30 ± 0.02a 0.34 ± 0.01
TAS (mmol/l) 0.24 ± 0.01 0.36 ± 0.03aaa 0.25 ± 0.01 0.22 ± 0.01
MDA/TAS (10–3) 1.76 ± 0.16 1.13 ± 0.23a 1.27 ± 0.09a 1.53 ± 0.05
3-NT (nmol/l) 42.42 ± 8.25 25.02 ± 3.58a 37.96 ± 7.31 42.26 ± 6.90
Results are means ± s.e.m. of n rats per group
CRP C-reactive protein; IL-1b interleukin 1b; IL-2 interleukin 2; MDA malondialdehyde; rhEPO recombinant human erythropoietin; TAS total
antioxidant status; TGF-b1 transforming growth factor b1; TNF-a tumour necrosis factor a and 3-NT 3-nitrotyrosine
a P \ 0.05, aa P \ 0.01 and aaa P \ 0.001 versus the sedentary group (control)
b P \ 0.05, bb P \ 0.01 and bbb P \ 0.001 versus the Swimming group without rhEPO (exercise: EX)
Histomorphological Analysis of Tissues from the
Suddenly Died Rat Under Exercise
and rhEPO Treatment
In the week 8 of exercise practice, one rat of the
EX ? rhEPO group suffered a sudden death episode in the
initial 15 min of the swimming session. All efforts with
reanimation procedures were, unfortunately, useless. As
the blood collection was compromised due the time taken
in the animal assistance, we removed and weighted the
kidneys, the lungs, the brain, the heart and the liver to
assess the possible cause of death. The rat heart weight was
1.82 g, and the heart/body weight ratio was 4.04 g kg-1,
significantly hypertrophic when compared with the values
of the EX group (1.23 ± 0.06 g and 2.66 ± 0.13 g kg-1,
respectively), demonstrating the tremendous effort of the
heart to maintain its functions. The histomorphological
studies provided the following results, when compared
with the normal lungs, brain, liver and left ventricle
(Fig. 2A1–A4, respectively): the kidneys from the sud-
denly died rat showed eosinophilia and congestion (data
not shown); the lungs showed signs of blood congestion,
alveolar haemorrhage and anoxia, without markers of
drowning (Fig. 2B1); the brain tissue from the suddenly
died rat demonstrated vascular congestion (Fig. 2B2); the
liver showed centre-lobular congestion and signals of
‘‘cardiac liver’’, probably due to the heart failure
(Fig. 2B3); there was LVH (2.0 mm3) when compared
with the values of the control group (1.5 mm3) and
deregulation of cardiac fibres, suggesting the hypothesis of
heart failure (eventually ventricular fibrillation) as cause of
death (Fig. 2B4).
Discussion
The rationale for the use of erythropoietin in sports as
doping is based on the increased oxygen capacity it pro-
vides, due to augmented erythropoietic stimulation (3).
Since rhEPO became available as an erythropoiesis-sti-
mulating drug, its abuse by athletes of endurance aerobic
sports has been speculated and studied [2, 5, 6]. rhEPO
doping remains one of the negative highlights of world
sport, with recurrent news about the distortion of sport
values and ethics by athletes, who desperate to enhance
their performance, trying illegally to improve oxygen
delivery to the muscles by using rhEPO [2, 14, 15]. In
endurance sports, such as long-distance running and
cycling and skiing, performance relies on an adequate O2-
supply to the heart and skeletal muscle. Hence, the rate of
maximal O2-uptake is an important determinant of aerobic
physical power. However, athletes who abuse rhEPO seem
to consider only the benefit to performance and ignore the
short and long-term side-effects. There is a suspicion that
rhEPO-induced erythrocytosis caused the death of about 20
world-class Dutch and Belgian Cyclists, although this was
never proven [8, 9], probably due to the lack of method-
ological capacity to distinguish between the endogenous
and the recombinant EPO as well as due the lack of
knowledge concerning the mechanisms underlying the side
effects of rhEPO. When Lasne and de Ceaurriz [4] were
able to separate and distinguish by electrophoresis the
endogenous and the rhEPO in human urine, the scandal of
rhEPO use in sports was revealed, and the research and
medical community was able to alert for the high health
risks for the athletes.
The main risks of erythrocytosis (Hct [ 0.55 l/l) include
heart failure, myocardial infarction, seizures, peripheral
thromboembolic events and pulmonary embolism. Endur-
ance athletes are at increased risk during the competition, if
their blood viscosity increases further due to the great loss
of fluid associated with sweating [6, 8, 9, 15]. Interestingly,
some deaths allegedly caused by rhEPO have not occurred
during exercise but during periods of physical inactivity,
suggesting that the deleterious effects are prolonged.
The consequences of physical exercise on the EPO
concentrations have been poorly investigated. However,
according to some data, exercise practise is able to reduce
the serum EPO levels [16]. In a study with marathon athletes
under rhEPO treatment, serum EPO concentrations were
increased after both 3 and 31 h after exercise but were
unchanged immediately after the end of running [17]. In our
study, the rats under chronic exercise practice and rhEPO
treatment showed several markers of increased cardiovas-
cular/thromboembolic risk. The increased RBC count ver-
sus the EX group without rhEPO treatment was confirmed,
as expected. This was accompanied by the development of
hypertension and tachycardia. Increased blood pressure is a
common feature in patients and athletes under rhEPO
treatment [6, 8, 9, 18] and might result both from increased
blood viscosity and loss of hypoxia-induced vasodilatation.
rhEPO treatment was also able to promote heart hypertro-
phy, which might be due to the blood hyperviscosity, sug-
gested by the RBC count increment, and could be viewed as
a need to ensure proper blood circulation to peripheral
tissues. Increased tachycardia might be explained by the
increment in sympathetic activity, revealed by the higher
values of plasma noradrenaline and adrenaline concentra-
tions. This effect of rhEPO was previously documented,
namely on haemodialyzed patients under rhEPO therapy
[19]. Furthermore, there was an increment in plasma
serotonergic measures, which might result from platelet
overactivation, thus releasing the granule contents. The
increased platelet reactivity was reported by others [7] and is
in favour of an increased vascular reactivity, blood pressure
and thromboembolic complications.

rhEPO has been successfully used in anaemic patients to
correct their anaemia. However, its effects on non-hema-
topoietic cells and tissues, such as the brain and the heart,
suggested new important insights to its use in other path-
ological conditions, such as the ischaemia–reperfusion,
heart failure and neurodegenerative diseases [20–25]. The
rationale for its potential use in those disorders is based on
its antioxidant, anti-apoptotic and anti-inflammatory prop-
erties, already known as ‘‘pleiotrophic actions’’ [26–29]. In
our study, both the rhEPO treatment, per se, and the
exercise practice have demonstrated a beneficial effect on
redox status markers. Therefore, rhEPO alone has pro-
moted a significant increment in serum antioxidant
capacity (TAS), together with a reduction in 3-nitrotyrosine
content, a marker of peroxynitrite formation, which is in
agreement with its action on other pathological circum-
stances [26–29]. Swimming rats also demonstrated anti-
oxidant effects, given by the reduction of serum lipid
peroxidation (MDA). In the rats under exercise and rhEPO
treatment, no relevant changes were encountered for the
redox status markers, being the values identical to those of
the control animals.
No significant changes were encountered in the serum
inflammatory markers, excepting the significant increment
in TGF-b1, a powerful profibrogenic cytokine, when
compared with the exercised rats without rhEPO treatment.
It is interesting to note that with exercise, there is adaptive
left ventricular hypertrophy, which might be rendered
pathologic (fibrosis) with rhEPO, creating substrate for
heart failure and sudden death from arrhythmias.
All the changes reported for the EX ? EPO rats seem to
be in agreement with the sudden death episode occurred in
one rat of the group, after 8 weeks of protocol, during the
initial minutes of exercise. The anatomo-pathological tissue
evaluation of the suddenly died rat demonstrated that there
were no drowning signs in the lungs, but marked vascular
congestion in the lungs, brain and liver. Furthermore, and
even more relevant, there was some LVH and deregulation
of cardiac fibres, together with a ‘‘cardiac liver’’, suggesting
the hypothesis of heart failure as the cause of death, which is
in agreement with the increased risk of cardio/cerebrovas-
cular and thromboembolic events that the functional studies
in the EX ? EPO also indicate. Further studies will be
important to assess the nature of the changes in myocardial
structure encountered in the rhEPO rats and in particular in
those suffering sudden dead episodes, in order to evaluate
the influence on myocyte size, capillary density and reactive
myocardial fibrosis, and its relationship with the deleterious
effects and mortality risk.
Our findings are in agreement with other studies, in both
humans and animals under rhEPO treatment. In end stage
chronic kidney disease patients, for example, rhEPO is able
to correct the associated anaemia, but there is haematocrit
increment, often associated with hypertension, thrombo-
embolism and higher morbidity and mortality [30]. In mice
transgenic for EPO, the increased haematocrit was linked
with left and right ventricular hypertrophy and cardiac
oedema, as well as with a reduced life expectancy [31].
Thus, erythrocytosis seems to increase the risk for myo-
cardial infarction and stroke, which was observed in our
experimental model of rhEPO sports doping in rats under
aerobic chronic exercise and rhEPO treatment.
In conclusion, rhEPO use, as doping, in situations of
chronic/regular physical exercise, promotes not only the
expected increased erythrocytosis, suggesting hypervis-
cosity, but also other serious deleterious cardiovascular and
thromboembolic modifications, such as hypertension, heart
hypertrophy, sympathetic and serotonergic overactivity.
Thus, our experimental model of rhEPO sports doping
demonstrates that athletes under similar conditions are
submitted to a serious cardiovascular and even mortality
risk, which might be known and believed by all sports
authorities and in particular by them and their physicians
and themselves.
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